Analysts project Stryker to report second-quarter earnings of $3.46 per share, a 10.5 percent increase year-over-year, according to consensus estimates released July 27, 2026.
Quarterly revenues for the medical technology firm are expected to reach $6.56 billion, up 8.9 percent from the same period last year.
>>> Pacific Storms Bring High Surf to Mexico and Hawaii
Over the past 30 days, analysts revised their consensus earnings per share estimate upward by 0.8 percent.
Robotics Launch Boosts Stock
The positive outlook follows Stryker's recent U. S.
launch of its Mako RPS handheld robotic system for total knee replacements.
The product expansion pushed the company's stock up 3.54 percent in a single day and 5.28 percent over 30 days to $330.25 per share.
However, the equity remains down 5.15 percent year-to-date.
Segment forecasts show strong growth in Orthopaedics net sales, expected to surge 31.5 percent year-over-year to $2.96 billion.
Within that segment, Trauma and Extremities sales are projected to rise 9.6 percent to $1.05 billion, while Hip sales are estimated to grow 6.6 percent to $496.90 million.
>>> Ocado Drops 190 Million Pound Dispute Against Marks and Spencer
In the MedSurg and Neurotechnology division, overall net sales are expected to decline 4.7 percent to $3.59 billion.
Sub-segment projections remain positive, with Instruments expected to climb 31.7 percent to $1.01 billion, Medical projected to rise 5.6 percent to $1.04 billion, and Endoscopy forecasted to grow 5.3 percent to $946.68 million.
Valuation models show a divergence between discounted cash flow estimates and traditional market multiples.
Independent financial analysis values Stryker at a fair value of $386.80 per share, indicating the stock is currently undervalued by approximately 15 percent based on long-term growth expectations from robotic-assisted surgery expansion.
Conversely, Stryker trades at a price-to-earnings ratio of 37.9x, above the U. S.
Medical Equipment industry average of 26.7x, the direct peer average of 28x, and the estimated fair ratio of 34.6x.
>>> US Stocks Mixed as Tech Selloff Offsets Crude Oil Plunge
Market analysts note that potential European regulatory delays and ongoing supply chain interruptions represent key operational risks that could impact future margin expansion and revenue realization.
